Optimal Strategies for Managing Prostate-specific Antigen Recurrence After Primary Radiotherapy in Prostate Cancer: The Finnish Perspective

Heikki Seikkula; Lauri Mäkelä; Harri Visapää; Mikael Anttinen

doi:10.1016/j.euf.2023.11.008

Optimal Strategies for Managing Prostate-specific Antigen Recurrence After Primary Radiotherapy in Prostate Cancer: The Finnish Perspective

Eur Urol Focus. 2023 Sep;9(5):698-700. doi: 10.1016/j.euf.2023.11.008. Epub 2023 Nov 21.

Authors

Heikki Seikkula¹, Lauri Mäkelä², Harri Visapää², Mikael Anttinen³

Affiliations

¹ Department of Surgery, Central Finland Wellbeing Services/Hospital Nova, Jyväskylä, Finland. Electronic address: heikki.seikkula@ksshp.fi.
² Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
³ Department of Urology, Turku University Hospital, Turku, Finland; Department of Urology, University of Turku, Turku, Finland.

PMID: 37989649
DOI: 10.1016/j.euf.2023.11.008

Abstract

Biochemical recurrence after radiotherapy for prostate cancer is a clinical dilemma. Patients at low risk of disease progression can be safely monitored. In Finland, options for those with reasonable life expectancy include salvage high-dose-rate brachytherapy and transurethral ultrasound ablation under magnetic resonance imaging guidance.

MeSH terms

Brachytherapy* / methods
Finland / epidemiology
Humans
Male
Neoplasm Recurrence, Local / pathology
Prostate-Specific Antigen
Prostatic Neoplasms* / pathology

Substances

Prostate-Specific Antigen